PD-1抑制剂替雷利珠单抗治疗晚期恶性肿瘤的药理作用与临床评价

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors

近年来,免疫治疗在恶性肿瘤领域取得了革命性突破,越来越多的新型免疫检查点抑制剂问世,彻底改变了恶性肿瘤的一线、二线和后线治疗选择。替雷利珠单抗是中国自主研发的PD-1抑制剂,该药在经典型霍奇金淋巴瘤、尿路上皮癌、非小细胞肺癌、肝细胞癌、食管鳞状细胞癌和胃癌/胃食管交界癌等肿瘤治疗中均表现出良好的抗肿瘤潜力和安全性。本文就替雷利珠单抗的结构与作用机制、药效学与药代动力学、临床研究及不良反应等方面的最新进展进行阐述,以期为临床医师提供借鉴和参考。

In recent years,immunotherapy has made breakthroughs in the field of malignant tumors,and more and more novel immune checkpoint inhibitors have been developed,revolutionizing the first-line,second-line and post-line treatment options for malignant tumors.Tislelizumab is a domestically developed inhibitor of programmed death-1(PD-1).The drug has shown good antitumor potential and safety in classical Hodgkin's lymphoma,uroepithelial carcinoma,non-small cell lung cancer,hepatocellular carcinoma,esophageal squamous cell carcinoma and gastric cancer/gastroesophageal junction carcinoma.In this review,the structure and mechanism of action,pharmacodynamics and pharmacokinetics,clinical research and adverse reactions of tislelizumab are reviewed to provide reference for clinical application.